Bausch Health, Canada Inc. Announces Additional Canadian Public Drug Plan Listings For UCERIS® (Budesonide) Aerosol Foam To Treat Mild To Moderate Distal Ulcerative Colitis In Adults
Portfolio Pulse from Benzinga Newsdesk
Bausch Health, Canada Inc. has announced additional Canadian public drug plan listings for UCERIS® (Budesonide) Aerosol Foam, which is used to treat mild to moderate distal ulcerative colitis in adults.
May 23, 2024 | 3:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bausch Health, Canada Inc. has expanded the availability of UCERIS® (Budesonide) Aerosol Foam through additional Canadian public drug plan listings, potentially increasing its market reach and revenue.
The additional listings on Canadian public drug plans for UCERIS® (Budesonide) Aerosol Foam are likely to increase the drug's accessibility and usage, potentially boosting Bausch Health's revenue and market presence in Canada.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80